China NT Pharma Group Co Ltd

China NT Pharma Group Co Ltd exhibits a highly leveraged capital structure, with total liabilities of CNY 6.21 billion and total equity of CNY -2.74 billion, resulting in a debt-to-equity ratio of -1.16. The company's liquidity position is weak, as evidenced by a current ratio of 0.02, indicating that it holds only CNY 0.02 in current assets for every CNY 1 of current liabilities. This is further compounded by a negative net cash position after subtracting total debt, which raises concerns about its ability to meet short-term obligations. Profitability metrics are mixed. The company reported a gross profit of CNY 9.61 billion, but this was insufficient to cover operating expenses, resulting in an operating income of CNY 1.59 billion. However, the net income is negative at CNY -2.6 billion, indicating a significant loss after all expenses, including interest and taxes. The return on equity (ROE) is 9.52%, which is positive but misleading due to the negative equity base. The return on assets (ROA) is -7.5%, suggesting that the company is not generating returns from its asset base. The company's revenue is concentrated in two segments: Digital Services and Sales Agency Service. The Digital Services segment focuses on marketing and promoting bone health knowledge, while the Sales Agency Service segment acts as an agent for medical and health-related products. There is no indication of geographic diversification in the provided data, and the company's exposure to a single business model may increase its vulnerability to market fluctuations. Looking ahead, the company's growth trajectory is uncertain. The most recent actual revenue was CNY 915.12 million, which is significantly lower than the reported revenue of CNY 24.16 billion. This discrepancy may indicate a need for further investigation into the company's financial reporting practices. Analysts have estimated a last actual EPS of CNY 0.74, but this does not align with the reported net loss of CNY 2.6 billion, suggesting potential volatility in earnings. The company's risk profile is elevated, with a medium liquidity risk and a negative net cash position. The risk assessment also highlights a low dilution risk, but the company's negative equity and high debt levels could lead to future dilution if it needs to raise additional capital. The company's financial structure and performance raise concerns about its long-term sustainability and ability to meet its obligations. Recent events, including the latest financial filings, indicate a significant net loss and a negative equity position. The company's financial statements show a substantial decline in profitability, with a net loss of CNY 2.6 billion. This raises questions about the company's financial health and its ability to generate sustainable earnings in the future.